These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34185908)

  • 1. A Call for Objective Dose Selection to Increase Success in Pediatric Clinical Trials: A Perspective From NICHD and NIMH Program Staff.
    Giacoia G; Grabb MC; Pawlyk AC; Ren Z; Samedy-Bates L; Taylor-Zapata P
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S9-S12. PubMed ID: 34185908
    [No Abstract]   [Full Text] [Related]  

  • 2. Progress in Drug Development-Pediatric Dose Selection: Workshop Summary.
    Wang J; van den Anker JN; Burckart GJ
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S13-S21. PubMed ID: 34185909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The European Medicines Agency Experience With Pediatric Dose Selection.
    Manolis E; Musuamba FT; Karlsson KE
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S22-S27. PubMed ID: 34185894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model-Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children.
    Vinks AA; Barrett JS
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S52-S59. PubMed ID: 34185897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012-2020.
    Green FG; Park K; Burckart GJ
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S28-S35. PubMed ID: 34185898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Data for Pediatric Pharmacometrics: Can We Upcycle Clinical Data for Research Use?
    Van Driest SL; Choi L
    Clin Pharmacol Ther; 2019 Jul; 106(1):84-86. PubMed ID: 30942897
    [No Abstract]   [Full Text] [Related]  

  • 7. Model-Informed Drug Development: A Regulatory Perspective on Progress.
    Zhu H; Huang SM; Madabushi R; Strauss DG; Wang Y; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):91-93. PubMed ID: 31162631
    [No Abstract]   [Full Text] [Related]  

  • 8. Minors and a Dawning Paradigm Shift in "Pediatric" Drug Development.
    Rose K; Tanjinatus O; Grant-Kels JM; Ettienne EB; Striano P; Neubauer D
    J Clin Pharmacol; 2021 Jun; 61(6):736-739. PubMed ID: 33368372
    [No Abstract]   [Full Text] [Related]  

  • 9. Adolescents and Drug Development: Commentary on a Dawning Paradigm Shift.
    Kearns GL; van den Anker JN
    J Clin Pharmacol; 2021 Jun; 61(6):740-743. PubMed ID: 33797778
    [No Abstract]   [Full Text] [Related]  

  • 10. Neonatal and Pediatric Dose Selection: Quo Vadis?
    Burckart GJ; van den Anker JN
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S7-S8. PubMed ID: 34185900
    [No Abstract]   [Full Text] [Related]  

  • 11. Status Toward the Implementation of Precision Dosing in Children.
    Barrett JS; Barrett RF; Vinks AA
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S36-S51. PubMed ID: 34185896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosing Recommendations for Pediatric Patients With Renal Impairment.
    Al-Khouja A; Park K; Anderson DJC; Young C; Wang J; Huang SM; Khurana M; Burckart GJ
    J Clin Pharmacol; 2020 Dec; 60(12):1551-1560. PubMed ID: 32542790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proceedings of a Workshop: US Food and Drug Administration-International Society of Pharmacometrics Model-Informed Drug Development in Oncology.
    Bruno R; Jin JY; Maxfield K; Milligan L; Liu C; Wang Y; McKee AE; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):81-83. PubMed ID: 30951201
    [No Abstract]   [Full Text] [Related]  

  • 15. Perspective on model-informed drug development.
    Lesko LJ
    CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1127-1129. PubMed ID: 34404115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Derisking Psychiatric Drug Development: The NIMH's Fast Fail Program, A Novel Precompetitive Model.
    Grabb MC; Cross AJ; Potter WZ; McCracken JT
    J Clin Psychopharmacol; 2016 Oct; 36(5):419-21. PubMed ID: 27404513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The coronavirus outbreak could make it quicker and easier to trial drugs.
    Ledford H
    Nature; 2020 Jun; 582(7811):172. PubMed ID: 32504019
    [No Abstract]   [Full Text] [Related]  

  • 18. Industry Perspective on Using MIDD for Pediatric Studies Requiring Integration of Ontogeny.
    Corriol-Rohou S; Cheung SYA
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S112-S119. PubMed ID: 31502694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
    Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
    AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerating the Global Development of Pediatric Cancer Drugs: A Call to Coordinate the Submissions of Pediatric Investigation Plans and Pediatric Study Plans to the European Medicines Agency and US Food and Drug Administration.
    Reaman G; Karres D; Ligas F; Lesa G; Casey D; Ehrlich L; Norga K; Pazdur R
    J Clin Oncol; 2020 Dec; 38(36):4227-4230. PubMed ID: 32946356
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.